SOSV is a global venture capital firm founded in 1995 and headquartered in Princeton, New Jersey. Specializing in seed-to-growth stage investments, SOSV operates multiple accelerator programs worldwide, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet ventures, Food-X for innovative food solutions, and dlab for blockchain technology. The firm focuses on investments in revolutionary deep technologies aimed at improving human and planetary health, as well as cross-border markets, particularly in Asia. SOSV invests in approximately 150 startups annually, providing support through its resources to accelerate product development and scaling. Over its two-decade history, SOSV has established a strong reputation, consistently ranking among the top venture capital firms globally.

RA Capital Management, L.P. is a Boston-based venture capital firm focused on growth capital and early-stage investments in the healthcare and life sciences sectors. Established in 2001, the firm specializes in funding companies involved in drug development, medical devices, diagnostics, and biotechnology. It engages in a range of investment stages, from seed funding to later rounds and public offerings, often preferring to co-invest and take board positions. RA Capital targets companies that are innovating in areas such as prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The firm is staffed by professionals with backgrounds in biology, chemistry, and medicine, providing them with a deep understanding of the scientific and regulatory landscape. This expertise allows RA Capital to identify promising technologies and offer strategic guidance, including potential partnerships and insights into public market demands.

Perceptive Advisors LLC is an investment management firm founded in 1999 and headquartered in New York City, with an additional office in Boston. The firm specializes in the healthcare sector, focusing on biotechnology, pharmaceuticals, life sciences, diagnostics, digital health, medical devices, and healthcare services. It engages in venture capital and incubation, investing at various stages of a company's life cycle, including seed and Series A funding, as well as late-stage venture and public market investments. Perceptive Advisors employs a long/short equity strategy and utilizes hedging techniques, including equity options and index options, while conducting in-house research to inform investment decisions. The firm also manages separate client-focused equity portfolios and provides customized debt financing solutions through its Perceptive Credit Opportunities Fund. Its clientele includes institutional investors, financial institutions, investment funds, and high-net-worth individuals.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.

Foresite Capital is a multi-stage investment firm specializing in healthcare and life sciences, managing approximately $2 billion in assets. The firm employs a rigorous, data-driven approach to investment analysis and collaborates closely with its portfolio companies, offering a diverse team of scientists, engineers, analysts, and clinicians. This collaborative model enables Foresite Capital to understand the distinct business models within the healthcare sector. The firm focuses on addressing significant unmet clinical needs by investing in promising healthcare and life sciences enterprises across various stages of development. Additionally, Foresite Capital prioritizes companies that leverage data science and machine intelligence to innovate within the healthcare landscape. The firm is headquartered in San Francisco, with an additional office in New York.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. As the strategic investment arm of Alexandria Real Estate Equities, it focuses on providing capital to seed, early-stage, and growth-stage companies within the healthcare sector. The firm emphasizes investments in biopharma, diagnostics, life sciences, research tools, agrifoodtech, and agtech. Alexandria Venture Investments aims to support innovative entities developing breakthrough technologies and therapies, leveraging its extensive industry knowledge and relationships with leading investors. Its approach is characterized by a commitment to fostering innovation and entrepreneurship in the life sciences and technology sectors.

Invus Financial Advisors, LLC is an employee-owned hedge fund sponsor based in New York, specializing in investments across various stages including special situations, venture capital, and growth equity. Founded in 2006, the firm manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong. Invus focuses on making minority investments and often acts as a lead investor or part of a consortium, emphasizing a flexible approach tailored to the unique needs of each company. The firm has a long-standing commitment to empowering owner-managers, aligning its incentives with those of its partners, and recognizing that meaningful business transformation requires time and resilience. With a history of reinvesting capital from European families since its inception, Invus demonstrates a dedication to fostering long-term relationships and navigating challenges in pursuit of extraordinary performance.

Casdin Capital, LLC is an investment firm specializing in the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, who serves as the Chief Investment Officer, the firm employs a fundamental research approach to manage a long-short equity fund. Casdin Capital invests across a spectrum of opportunities, ranging from early-stage to late-stage private investments. As of October 2020, the firm manages approximately $2.2 billion in assets.

Fidelity Investments is a privately owned investment manager based in Boston, Massachusetts, founded in 1946. The firm offers a wide range of financial services, including individual retirement accounts, 401(k) rollovers, annuities, discount brokerage, and wealth management. It serves a diverse clientele, including individual investors, businesses, financial advisors, and institutions. Fidelity manages equity, fixed income, and balanced mutual funds, investing in public equity and fixed income markets worldwide. The firm conducts in-house research to guide its investment decisions and supports over 32 million clients in achieving their financial goals. Additionally, Fidelity assists more than 22,000 businesses with employee benefit programs and collaborates with over 13,000 financial institutions to provide innovative investment and technology solutions.

ARCH Venture Partners, L.P. is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois, with additional offices across North America and South America. The firm specializes in early-stage and growth capital investments, primarily focusing on life sciences and biotechnology, but also covering a wide array of technology sectors such as advanced materials, communications technologies, and information technology. ARCH is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. It has raised over $3 billion through ten venture funds and has invested in more than 150 companies, often co-founding them with leading scientists and entrepreneurs. The firm typically invests between $50,000 and $150 million per company, aiming to enter at seed rounds to minimize risk, and seeks a seat on the Board of Directors for its portfolio companies. While primarily investing in the United States, ARCH also targets opportunities in Canada, Europe, and select countries in Asia, focusing on underserved geographic markets rich in scientific research and technological talent.

Sequoia Capital is a prominent venture capital firm founded in 1972 and based in Menlo Park, California. The firm specializes in investing across various stages of startups, including seed, early, and growth stages, and focuses on sectors such as technology, healthcare, financial services, internet, and mobile. Sequoia typically invests between $100,000 and $1 million in seed companies, $1 million to $10 million in early-stage ventures, and $10 million to $100 million in growth investments. The firm operates globally, with significant activities in regions like Israel, China, and India, where it partners with dynamic founders to build successful companies. Sequoia's extensive portfolio includes notable firms and offers valuable insights and resources, benefiting from decades of experience in the venture capital landscape.

Janus Henderson Group plc is a global asset management firm based in London, with additional offices in Jersey and Sydney. Founded in 1934, the company provides a range of investment services to institutional, retail, and high net worth clients. It manages client-focused equity and fixed income portfolios, as well as equity, fixed income, and balanced mutual funds. The firm invests in public equity and fixed income markets, along with real estate and private equity opportunities. As of March 2018, Janus Henderson manages approximately £265.3 billion in assets and employs over 2,000 staff worldwide, dedicated to helping clients achieve their long-term financial objectives.

T. Rowe Price is a publicly owned investment management firm founded in 1937 and headquartered in Baltimore, Maryland. The company serves a diverse clientele that includes individuals, institutional investors, retirement plans, and financial intermediaries. T. Rowe Price offers a wide array of investment strategies encompassing equity, fixed income, and private equity, with a particular focus on funding technology startups. The firm employs a combination of fundamental and quantitative analysis to guide its investment decisions, utilizing both in-house and external research. Additionally, T. Rowe Price is committed to socially responsible investing, prioritizing environmental, social, and governance factors. With a global presence, the firm operates offices in numerous locations worldwide, enhancing its ability to navigate various markets and deliver reliable investment solutions.

Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, a co-founder of Sun Microsystems. Based in Menlo Park, California, the firm manages over $5 billion and primarily invests in early-stage technology companies throughout the United States. Khosla Ventures provides capital, strategic advice, and venture assistance to entrepreneurs focused on breakthrough innovations across various sectors, including consumer technology, enterprise solutions, health, education, agriculture, and sustainable energy. The firm has a particular interest in high-risk, high-reward opportunities, often acting as a sole investor in "science or innovation experiments." Investment sizes typically range from $100,000 to over $20 million, allowing Khosla Ventures to support both traditional ventures and unconventional projects.

GV Management Company, LLC, established in 2009 as the venture capital arm of Alphabet Inc., specializes in investments across various stages, including seed, early, and late-stage funding. Based in Mountain View, California, with additional offices in Boston, New York, Seattle, Cambridge, and London, GV focuses on sectors such as life sciences, healthcare, artificial intelligence, robotics, transportation, cybersecurity, and agriculture. The firm has invested in over 300 companies, aiming to drive innovation and improve lives. GV seeks to make investments of up to $50 million, while offering early-stage startups funding of up to $250,000, typically taking minority stakes in these companies. Through its extensive network, GV provides startups with unique access to technology and talent, enhancing their potential for success.

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Atlas Venture L.P. is a private equity and venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in early-stage investments, primarily in the life sciences and technology sectors. In life sciences, Atlas Venture focuses on biotechnology, therapeutics, medical technologies, and personalized medicine. In technology, it targets areas such as fintech, consumer innovation, and emerging web services. The firm employs a seed-led venture creation strategy that emphasizes rigorous selection of promising startups led by capable entrepreneurs. Atlas Venture typically invests between $500,000 and $5 million in its portfolio companies, often taking the lead role and seeking board representation. The firm manages over $2 billion in committed capital and has been involved with more than 350 companies across various countries. Its investment strategy prioritizes opportunities in the United States, particularly in regions such as New England and California.

The Redmile Group, established in 2007 and based in San Francisco with an additional office in New York, is a private equity firm specializing in venture capital investments within the healthcare sector. The firm manages multiple funds, including Redmile Biopharma Investments II and III, which focus specifically on the biopharma industry. Redmile Group aims to identify and support innovative healthcare companies, leveraging its expertise to foster growth and development in this critical field.

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it is part of the legacy of Fidelity Investments, one of the largest asset management firms in the world. F Prime focuses on investing in North American and European companies across various sectors, including healthcare, life sciences, medtech, technology, and health information technology. The firm operates several specialized funds, such as those dedicated to healthcare and life sciences, which aim to support early-stage companies in these industries. With a commitment to fostering entrepreneurship, F Prime leverages its extensive insights, domain expertise, and relationships to assist entrepreneurs in building impactful companies, all while avoiding the pressures of external fundraising.

New Enterprise Associates, Inc. is a private equity and venture capital firm established in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investments across various stages of company development, including seed, start-up, early stage, and later stage, with a focus on sectors such as information technology, healthcare, and energy technology. NEA's investment strategy encompasses a wide range of industries, including consumer internet, software, biotechnology, medical devices, and alternative energy. With over $19 billion in cumulative committed capital, the firm has a notable track record, having participated in more than 210 portfolio company IPOs and over 360 acquisitions. NEA aims to invest between $0.05 million and $20 million, targeting both domestic and international markets, particularly in Asia and the Americas.

The Bill & Melinda Gates Foundation is a prominent grant-making organization co-founded by Bill and Melinda Gates in 2000, headquartered in Seattle, Washington, with additional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. The foundation focuses on improving global health, enhancing education, and providing support to at-risk families, particularly in the Pacific Northwest. It actively promotes strategies that assist low-income families and works towards greater equality in various sectors. The foundation is also involved in investment management, overseeing an endowment that includes a diverse portfolio primarily in public equity and fixed income markets, while excluding tobacco-related investments. Its trustees include Bill Gates, Melinda Gates, and Warren Buffett.

Wellington Management Company LLP, founded in 1928 and headquartered in Boston, Massachusetts, is a prominent investment management firm providing comprehensive solutions to institutional clients worldwide. The firm specializes in a diverse range of investment strategies, including equity, fixed income, multi-asset, and alternative investments, tailored to meet the unique return and risk objectives of its clients. Wellington Management employs a collaborative approach, leveraging proprietary research and analytical tools to identify opportunities and manage risks across global capital markets. The firm caters to a wide array of clients, including sovereign institutions, endowments, foundations, wealth managers, and insurance companies, spanning more than 50 countries. With a focus on long-term investment principles, Wellington Management fosters independent thought and debate within its teams, ensuring that resources are effectively utilized to deliver consistent results. The firm also emphasizes environmental, social, and governance (ESG) considerations in its research and investment processes, engaging with companies on key ESG topics.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.

Polaris Partners is a venture capital firm founded in 1996 and headquartered in Boston, Massachusetts. With a focus on technology and healthcare sectors, Polaris invests in companies at all stages of development, from inception to profitable growth. The firm has a history of partnering with experienced entrepreneurs and innovators, aiming to enhance the way people live and work. In addition to its Boston headquarters, Polaris has offices in San Francisco and New York, and it actively targets investments in life sciences, biotechnology, and software industries across the United States and Europe. Over its more than two-decade history, Polaris Partners has established itself as a multibillion-dollar investment firm committed to fostering innovation and entrepreneurship.

Flagship Pioneering, established in 2000 and based in Cambridge, is a venture capital firm that focuses on creating and developing innovative companies in healthcare, technology, renewable energy, and agriculture. The firm is dedicated to conceiving and nurturing first-in-category ventures aimed at transforming human health and sustainability. By leveraging science and entrepreneurial expertise, Flagship Pioneering explores unconventional ideas and guides them toward impactful outcomes through an evolutionary approach. The firm emphasizes the integration of innovative thinking, entrepreneurial leadership, and effective capital management to systematically generate groundbreaking companies. Additionally, Flagship Pioneering is committed to attracting and cultivating top talent in the scientific, entrepreneurial, and managerial fields, ensuring a robust foundation for its ventures.

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..

SoftBank Group Corp. is a multinational telecommunications and internet corporation based in Tokyo, Japan. Established in 1981, it provides a wide range of services including mobile and fixed-line communications, broadband, and digital television. The company operates through several segments, including the SoftBank Vision Fund, which focuses on investing in technology sectors such as artificial intelligence, robotics, and fintech. Additionally, SoftBank manufactures and distributes mobile devices and offers services in e-commerce, internet advertising, and IT solutions. The firm also engages in renewable energy by generating and supplying electricity. Beyond telecommunications, SoftBank has interests in various sectors, including media, professional sports, and fashion through platforms like ZOZOTOWN. With a global presence, SoftBank actively invests in growth-stage companies, aiming to foster innovation and technological advancement across diverse industries.

Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector, including biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. Over its 45-year history, the firm has financed nearly 500 companies, primarily targeting start-ups, early-stage ventures, corporate spin-offs, and occasional turnaround situations. Sofinnova Partners actively sources investment opportunities and often serves as the first institutional investor in Series A financings, taking a lead role in its portfolio companies. The firm engages closely with entrepreneurs from the formation phase, holding board positions and guiding companies through their development until exit. While primarily investing throughout Europe, Sofinnova Partners also allocates a portion of its investments globally.

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in the life sciences and healthcare sectors, primarily targeting opportunities in China but also considering ventures in other parts of East and South Asia. Lilly Asia Ventures seeks to invest in companies at various stages, from seed to later stages, with a preference for those showcasing strong management teams and innovative technologies or business models. The investment strategy emphasizes human therapeutics, medical technology, healthcare services, and broader life sciences. Typically, investments range from $5 million to $15 million per round, with an inclination towards acquiring minority stakes, usually under 20 percent. The firm aims to play an active role in its portfolio companies by seeking board seats or observation rights.

Northpond Ventures is a venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. Founded in 2018, the firm specializes in growth capital investments across various sectors, including life sciences, biotechnology, diagnostics, digital health, and emerging technologies. Northpond Ventures aims to support innovative companies that are poised to make significant advancements in healthcare and technology, with a focus on building a better future through its strategic investments. As a Registered Investment Adviser, the firm is committed to fostering developments in therapeutics, artificial intelligence, machine learning, and medical technology.

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

Leaps by Bayer is focused on making transformative advancements in the life sciences, particularly within biotechnology, agriculture, and scientific innovation. Established in 2015 and headquartered in Leverkusen, Nordrhein-Westfalen, the firm aims to invest in groundbreaking technologies that have the potential to significantly improve human life. Leaps by Bayer targets high-impact projects that may currently seem unattainable, acknowledging that setbacks and failures are a natural part of pursuing such ambitious goals. Through sustained investments in disruptive biotechnologies, the organization seeks to drive progress that could fundamentally change the world for the better.

Illumina Ventures is a California-based venture capital firm founded in 2016, specializing in early-stage investments in the life sciences and healthcare sectors. The firm operates as an independently managed fund in strategic partnership with Illumina, which provides significant capital and access to its expertise in genomics. Illumina Ventures focuses on investing in companies that are pioneering applications of nucleic acid sequencing and developing innovative products that enhance the genomics ecosystem, including tools, diagnostics, and therapeutics. The firm typically invests between $5 million and $10 million and collaborates with other leading institutional and strategic investors. Its investment areas encompass life science research, healthcare, agriculture, environmental science, public safety, and personal wellness, aiming to leverage genomics to improve human health.

Takeda Pharmaceutical Company Limited, founded in 1781 and headquartered in Tokyo, Japan, is a leading research-based pharmaceutical company. It operates primarily in the pharmaceutical sector, focusing on five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which contribute to over 80% of its revenue. Takeda's diverse product portfolio includes established medications for conditions such as prostate cancer, peptic ulcers, hypertension, and diabetes. Additionally, Takeda Ventures, Inc., the company's venture capital arm, invests in therapeutic innovations across various stages of development, primarily in the United States, Canada, and Europe. The firm prioritizes investments in drug and biotherapeutic technologies, with a particular interest in cardiometabolic, central nervous system, chronic inflammatory, and oncology domains, while avoiding sectors like diagnostics and anti-infective products. In fiscal 2023, Takeda reported revenue of approximately JPY 4.3 trillion, with a significant portion generated from its operations in the US, Japan, and Europe.

Versant Ventures is a prominent healthcare investment firm headquartered in California, specializing in medical devices, biotechnology, and pharmaceuticals. Established in 1999, the firm manages approximately $2.3 billion and invests across all stages of company development, with a strong focus on discovering and developing innovative therapeutics. Versant has a global presence with offices in Canada, the U.S., and Europe, and its team comprises professionals with extensive investment, operational, and scientific expertise, allowing for a proactive approach to building companies. Since its inception, Versant has successfully facilitated the growth of over 65 companies, leading to numerous acquisitions and public offerings.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in the United States. The firm specializes in investing in both early-stage and late-stage biotechnology companies, focusing on the entire drug development lifecycle, from preclinical discovery to clinical and commercial stages. Boxer Capital targets private and public companies within the biotechnology sector, providing capital to support their growth and development. It operates as a subsidiary of Tavistock Life Sciences, leveraging its resources and expertise to foster innovation in the biotechnology field.

Deerfield is an investment management firm established in 1994 that specializes in advancing healthcare through investment, information, and philanthropy. With over $8 billion in funds, Deerfield invests broadly in both public and private healthcare sectors, targeting a diverse range of companies from early-stage drug research to established healthcare services and medical device firms. The firm typically maintains equity or debt interests in more than 100 companies. It employs the Deerfield Institute, which conducts extensive research to provide objective market intelligence, engaging with thousands of professionals annually to address complex healthcare challenges. Additionally, a portion of the firm's profits is allocated to the Deerfield Foundation to support various philanthropic initiatives.

DCVC, founded in 2010 and based in Palo Alto, California, is a venture capital firm that invests in seed and early-stage companies across various sectors, including artificial intelligence, exascale computing, climate, engineering, materials science, robotics, space, water, biology, defense, security, and deep tech. The firm leverages a unique team of experienced venture capitalists, technology entrepreneurs, and practicing engineers, bringing together over 35 technology executives and experts from prestigious institutions. DCVC also operates a dedicated fund, DCVC Bio, which focuses on early-stage startups in computational biology, aiming to harness advancements in genetic sequencing, artificial intelligence, and automation to drive innovation in synthetic biology, medicine, and agriculture. With a proven track record of over 150 companies and 40 material exits, DCVC is committed to fostering deep technological changes that enhance life sciences and IT infrastructure.

Civilization Ventures is a venture capital firm based in San Francisco, California, founded in 2017. The firm focuses on investing in pioneering founders who are shaping the future of health technology and biology-driven innovation. Civilization Ventures aims to be the initial investor and lead supporter of disruptive companies in sectors such as digital health, synthetic biology, diagnostics, 3D bio-printing, and AI/software-enabled health technology. The team consists of experienced entrepreneurs and industry leaders dedicated to fostering the success of their portfolio companies.

EcoR1 Capital, LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. The firm also manages separate client-focused equity and fixed income portfolios. The firm invests in the public equity markets of the United States. It employs long/short strategy to make its investments. The firm typically invests in companies in biotechnology sector. EcoR1 Capital, LLC was founded in 2012 and is based in San Francisco, California.

Decheng Capital LLC is a private equity and venture capital firm established in 2012, with its headquarters in Menlo Park, California, and additional offices in Shanghai, China, and New York, New York. The firm focuses on early-stage and growth capital investments primarily in the life sciences and healthcare sectors, including life science tools, biopharmaceuticals, medical devices, diagnostics, digital health technologies, and agricultural biotechnology. Decheng Capital aims to leverage its expertise and strategic support to help innovative companies in these fields thrive, particularly in China. With over $1 billion in capital under management, the firm is well-positioned to capitalize on opportunities arising from the rapid growth of the healthcare industry and advancements in life science research.

Vivo Capital, LLC is a private equity and venture capital firm established in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. The firm specializes in investing in healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, primarily focusing on companies in the United States and East Asia. Vivo Capital manages approximately $5.8 billion in assets and has invested in over 290 public and private companies globally. The firm employs a multi-fund investment strategy, targeting various financing stages from early-stage ventures to public companies, and typically invests between $2 million and $40 million. Vivo Capital's team consists of more than 50 professionals with diverse expertise in medical, scientific, and entrepreneurial fields, allowing the firm to identify and nurture high-quality companies within the healthcare industry.

Founded in 1969 as the venture capital arm of the Rockefeller family, Venrock specializes in seed and early-stage investments primarily in the technology and healthcare sectors. The firm has a history of partnering with entrepreneurs to build successful and enduring companies. Its notable portfolio includes industry leaders such as Apple Computer, Athenahealth, Gilead Sciences, and Illumina, among others. Venrock operates from Palo Alto, California, and manages various funds focused on early-stage ventures as well as later-stage investments in healthcare. The firm remains committed to identifying innovative companies across information technology, media, energy, emerging technologies, and life sciences.

Kurma Partners is a Paris-based venture capital firm established in 2009, focusing on early-stage investments in the healthcare and biotechnology sectors across Europe. The firm specializes in financing innovation from pre-creation to development capital, managing multiple funds, including the Kurma Biofund I, II, and the Kurma Diagnostics fund. Kurma Partners plays a significant role in supporting therapeutic and medical innovations, leveraging connections with leading research institutes and prestigious hospitals. The firm's investment interests encompass a wide range of areas, including oncology, life sciences, digital health, artificial intelligence, and big data, demonstrating a commitment to advancing healthcare technologies.

Pfizer is one of the largest pharmaceutical companies in the world, founded in 1849 and headquartered in the United States. The company is dedicated to improving health and well-being by applying scientific advancements and global resources. Pfizer manufactures and sells a diverse range of healthcare products, primarily focusing on prescription drugs and vaccines, which account for the majority of its sales. Notable products include the pneumococcal vaccine Prevnar 13, the cancer treatment Ibrance, and the cardiovascular drug Eliquis. With annual sales nearing $50 billion, Pfizer has a strong international presence, with nearly half of its sales derived from global markets, particularly emerging economies. The firm is committed to providing access to safe, effective, and affordable medicines to enhance patient outcomes and address pressing healthcare challenges.

IMM Investment Corp. is a private equity and venture capital firm based in Seoul, South Korea, established in 1999. The firm specializes in mezzanine investments and focuses on sectors such as information technology, healthcare, biotechnology, and manufacturing. It engages in various investment activities including mergers and acquisitions, corporate restructuring, management buyouts, and cross-border investments. In its growth stage investments, IMM allocates resources to startups, expansion, and mezzanine financing, with a significant emphasis on information technology infrastructure and digital content. The firm also targets medium-sized companies and prefers an active management role in its investments. Additionally, IMM Investment undertakes secondary investments and co-invests in buyout transactions, aiming for strategic opportunities in diverse industries, including telecommunications, entertainment, and biotechnology.

MPM Capital is a healthcare investment firm founded in 1996 and headquartered in Cambridge, Massachusetts, with additional offices in Brisbane, California. The firm specializes in early-stage investments in the biotechnology, healthcare, and life sciences sectors, focusing primarily on innovative therapeutic technologies in oncology, immunology, and neuroscience. MPM Capital invests in both private and public companies, targeting areas such as medical technology, specialty pharmaceuticals, and diagnostics. The firm engages in seed and early-stage financing, as well as late-stage investments in biopharmaceuticals with clinical proof-of-concept data. MPM Capital typically invests between $5 million and $50 million and aims to be a lead investor, often taking interim operating positions within its portfolio companies. Its global investment strategy emphasizes North America, Western Europe, and Asia, particularly India, with a commitment to translating scientific advancements into effective medical solutions that improve patient outcomes.

Lyfe Capital is a healthcare venture capital firm founded in 2015, headquartered in Shanghai, China. The firm specializes in investing in biotechnology, pharmaceuticals, medical devices, diagnostic equipment, healthcare services, and digital health companies. Lyfe Capital focuses on businesses that have established product foundations and require additional capital to accelerate growth, particularly in Greater China. The firm offers not only financial support but also assists its portfolio companies with market planning, talent acquisition, global expansion, and partnerships. With multiple funds, including those launched in 2017 and 2020, Lyfe Capital aims to target opportunities primarily in the United States and Asia, contributing to the advancement of innovative healthcare solutions.

Samsara BioCapital LLC is a private equity firm established in 2016 and located in Palo Alto, California. The firm specializes in investing in biotechnology companies across the United States, providing capital and strategic support to help advance innovations in the life sciences sector. Samsara BioCapital aims to identify and cultivate promising biotechnological advancements that can transform healthcare and improve patient outcomes.

Osage Partners LLC is a private equity and venture capital firm established in 1990, based in Bala Cynwyd, Pennsylvania, with an additional office in Princeton, New Jersey. The firm specializes in early-stage, mid-venture, and late-stage investments, primarily focusing on technology and healthcare sectors. It seeks to invest in a wide range of areas including business-to-business software, life sciences, healthcare IT, medical devices, diagnostics, and advanced materials. Osage Partners typically invests between $1 million to $4 million in companies with annual revenues ranging from $500,000 to $3 million, with a preference for leading investment rounds. The firm emphasizes partnerships with research universities to support startups that commercialize university technologies, having collaborated with over 80 institutions, including many of the top research universities in the U.S. Osage Partners is committed to actively participating in the governance of its portfolio companies to foster growth and innovation.